MedTech & Diagnostics
Henry Schein Executive Compensation (FY25)
HSIC · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 22, 2026
200 figures on this page: 189 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Stanley Bergman: $11,640,272 → $12,013,915 (3.2% higher)
Say-on-pay support: 85.7% → 97.9% (12.2 points higher)
Frequently asked questions
Answers drawn from the data on this page.
What was Henry Schein's say-on-pay result?
Shareholders supported the say-on-pay proposal with 97.9% of votes cast including abstentions in favor at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Henry Schein's peer group?
The disclosed peer group names Avantor, Inc., Baxter International Inc., Cardinal Health, Inc., Cencora, Inc. and DaVita Inc., among others.
What is Henry Schein's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 152:1, against median employee compensation of $78,954.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Stanley Bergman Chairman and Former Chief Executive Officer (Principal Executive Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mark Mlotek Executive Vice President and Chief Strategic Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Ettinger Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Ronald South Senior Vice President and Chief Financial Officer (Principal Financial Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Stanley Bergman Chairman and Former Chief Executive Officer (Principal Executive Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mark Mlotek Executive Vice President and Chief Strategic Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Ettinger Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Ronald South Senior Vice President and Chief Financial Officer (Principal Financial Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Stanley Bergman Chairman and Former Chief Executive Officer (Principal Executive Officer) Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mark Mlotek Executive Vice President and Chief Strategic Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Ettinger Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrea Albertini Chief Executive Officer, Global Distribution and Technology | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Ronald South Senior Vice President, Chief Financial Officer (Principal Financial Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrea Albertini | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Mark E. Mlotek | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Michael S. Ettinger | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Ronald N. South | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
| Stanley M. Bergman | PSU | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mark Mlotek | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Ronald South | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Michael Ettinger | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Andrea Albertini | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Philip A. Laskawy Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Deborah Derby | ◇ | ◇ | — | — | — | — | ◇ |
Joseph L. Herring | ◇ | ◇ | — | — | — | — | ◇ |
Kurt P. Kuehn | ◇ | ◇ | — | — | — | — | ◇ |
Mohamad Ali | ◇ | ◇ | — | — | — | — | ◇ |
Scott P. Serota | ◇ | ◇ | — | — | — | — | ◇ |
Anne H. Margulies | ◇ | ◇ | — | — | — | — | ◇ |
Carole T. Faig | ◇ | ◇ | — | — | — | — | ◇ |
Robert J. Hombach | ◇ | ◇ | — | — | — | — | ◇ |
William K. Dan Daniel | ◇ | ◇ | — | — | — | — | ◇ |
Max Lin | ◇ | — | — | — | — | — | ◇ |
Carol Raphael, Frederick M. Lowery, Bradley T. Sheares, Stanley M. Bergman and Reed V. Tuckson served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
| Committee meeting fee | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Avantor, Inc. AVTR
- Baxter International Inc. BAX
- Cardinal Health, Inc. CAH
- Cencora, Inc. COR
- DaVita Inc. DVA
- Dentsply Sirona Inc. XRAY
- Encompass Health Corporation EHC
- Genuine Parts Company GPC
- Insight Enterprises, Inc. NSIT
- Laboratory Corporation of America Holdings symbol not shown
- Owens & Minor, Inc. ACH
- Patterson Companies, Inc. PDCO
- Quest Diagnostics Incorporated DGX
- Select Medical Holdings Corporation SEM
- Steris PLC STE
- Tenet Healthcare Corporation THC
- Universal Health Services, Inc. UHS
- US Foods Holding Corp. USFD
- W.W. Grainger, Inc. GWW
- WESCO International, Inc. WCC
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 21, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 23, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 18, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 13, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 21, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 22, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 31, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 31, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | May 31, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Henry Schein disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Henry Schein sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
200 figures on this page: 189 cited to the filing that reported them, 11 calculated from figures it prints.
189 cited to the filing
11 calculated from the filing
Documents cited
- 0001193125-26-235496
- 0001193125-26-146317CEO Pay Ratio · Director Compensation for Fiscal 2025 · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table for Fiscal 2025, Fiscal 2024 and Fiscal 2023 1 · and 1 more section
- 0001193125-25-125917
- 0001193125-25-076253Summary Compensation Table for Fiscal 2024, Fiscal 2023 and Fiscal 2022 1
- 0001193125-24-147029
- 0001193125-24-091374Summary Compensation Table for Fiscal 2023, Fiscal 2022 and Fiscal 2021 1
- 0001193125-23-154352
- 0001193125-22-156133
- 0001193125-21-162809
- 0001193125-20-151575
- 0001193125-19-155351
- 0001193125-18-181713
- 0001193125-17-191223
- 0001193125-16-609605
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Henry Schein executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/HSIC (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Henry Schein and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Henry Schein discloses
The companies named in HSIC's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}